BASF and CTIBiotech announce first results of 3D human sebaceous glands technology

The two companies say that experts have demonstrated both ex vivo production of physiological sebum in 3D human sebaceous gland model and its regulation by means of active ingredients.

“After two years of research, the experts have now demonstrated both the ex vivo production of physiological sebum in a long term culture of a 3D human sebaceous gland model, and the regulation of this sebum production by means of active ingredients​,” they explain.

“Using CTIBiotech’s 3D human sebaceous gland technology, scientists were able to improve BASF’s 3D skin model portfolio. The new 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders​.”

Why sebaceous glands?​

The role of the sebaceous glands in skin homeostasis is of keeping the skin moist and protecting the organ against external influences.

These include the impact of things like harsh weather, pollution and microbial assaults, say the two companies, with the production of sebum from the glands lubricating and softening the skin and hair.

How do 3D models improve testing options for cosmetics applications?​

The 3D models can be used for testing new ingredients or formulations, and the companies say that compared to current in vitro​ methods, the 3D models they have developed allow analysis that is “more in touch with human physiology and sebaceous gland metabolism​.”

BASF’s project lead Dr. Sabine Pain explains the benefit of this: “That’s how their technology helps us accelerate the development of innovative and highly reliable ingredients for the skin care market. ​

“Our understanding of sebaceous gland metabolism provides the basis for developing and testing advanced cosmetic bio-actives for skincare applications, and in particular skincare products for oily skin.”​

The two organisations are looking to build on the partnership and technology, according to Professor Colin McGuckin, Chief Scientific Officer and President of CTIBiotech.

“The next evolution of the sebaceous gland model will be based on a 3D bio-printing technology that allows ​us to fully reproduce micro-glands into a full thickness skin model, in vitro,​” he predicts.